APA (7th ed.) Citation

H, S., X, S., H, L., Y, W., Y, Y., Y, X., . . . F, F. (2025, February). Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial. International Journal of Women's Health.

Chicago Style (17th ed.) Citation

H, Su, Shang X, Liu H, Wang Y, Yu Y, Xu Y, Jiang K, and Feng F. "Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial." International Journal of Women's Health Feb. 2025.

MLA (9th ed.) Citation

H, Su, et al. "Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial." International Journal of Women's Health, Feb. 2025.